For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
The closing price of Silence Therapeutics Plc ADR (NASDAQ: SLN) was $2.18 for the day, down -5.22% from the previous closing price of $2.30. In other words, the price has decreased by -$5.22 from its previous closing price. On the day, 0.54 million shares were traded. SLN stock price reached its highest trading level at $2.525 during the session, while it also had its lowest trading level at $2.16.
Ratios:
Our analysis of SLN’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 9.31 and its Current Ratio is at 9.31. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Goldman on February 11, 2025, initiated with a Sell rating and assigned the stock a target price of $6.
On September 03, 2024, Jefferies started tracking the stock assigning a Buy rating and target price of $40.Jefferies initiated its Buy rating on September 03, 2024, with a $40 target price.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SLN now has a Market Capitalization of 112821760 and an Enterprise Value of 222552336. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.00 while its Price-to-Book (P/B) ratio in mrq is 0.81. Its current Enterprise Value per Revenue stands at 5.145 whereas that against EBITDA is -4.543.
Stock Price History:
The Beta on a monthly basis for SLN is 1.27, which has changed by -0.90250444 over the last 52 weeks, in comparison to a change of 0.049593568 over the same period for the S&P500. Over the past 52 weeks, SLN has reached a high of $24.38, while it has fallen to a 52-week low of $2.28. The 50-Day Moving Average of the stock is -48.05%, while the 200-Day Moving Average is calculated to be -82.01%.
Shares Statistics:
SLN traded an average of 286.72K shares per day over the past three months and 315780 shares per day over the past ten days. A total of 47.21M shares are outstanding, with a floating share count of 37.56M. Insiders hold about 20.46% of the company’s shares, while institutions hold 32.98% stake in the company. Shares short for SLN as of 1741910400 were 1408991 with a Short Ratio of 4.91, compared to 1739491200 on 1429780. Therefore, it implies a Short% of Shares Outstanding of 1408991 and a Short% of Float of 4.68.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
Silence Therapeutics Plc ADR (SLN) is presently subject to a detailed evaluation by 3.0 analysts, each offering their unique perspectives on its market standing.The consensus estimate for the next quarter is -$0.32, with high estimates of -$0.11 and low estimates of -$0.45.
Analysts are recommending an EPS of between -$0.23 and -$1.8 for the fiscal current year, implying an average EPS of -$1.06. EPS for the following year is -$1.36, with 3.0 analysts recommending between -$0.72 and -$1.9.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 4 analysts. It ranges from a high estimate of $6M to a low estimate of $868.26k. As of the current estimate, Silence Therapeutics Plc ADR’s year-ago sales were $12.41MFor the next quarter, 4 analysts are estimating revenue of $3.57M. There is a high estimate of $6M for the next quarter, whereas the lowest estimate is $824.69k.
A total of 7 analysts have provided revenue estimates for SLN’s current fiscal year. The highest revenue estimate was $84.54M, while the lowest revenue estimate was $3.35M, resulting in an average revenue estimate of $25.59M. In the same quarter a year ago, actual revenue was $34.27MBased on 5 analysts’ estimates, the company’s revenue will be $18.02M in the next fiscal year. The high estimate is $37.55M and the low estimate is $3.22M.
